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574Donor Serostatus Has an Impact on Cytomegalovirus-
Specific Immunity, Cytomegaloviral Disease Incidence,
and Survival in Seropositive Hematopoietic
Cell Transplant Recipients
Alejandra Ugarte-Torres,1 Mette Hoegh-Petersen,1 Yiping Liu,1 Feng Zhou,1
Tyler S. Williamson,2 Diana Quinlan,3 Sarah Sy,1 Lina Roa,1 Faisal Khan,1
Kevin Fonseca,4 James A. Russell,3 Jan Storek1,3More cytomegalovirus (CMV)-specific T cells are transferred with grafts from CMV seropositive than sero-
negative donors. We hypothesized that seropositive recipients of grafts from seropositive donors (D1R1)
have higher counts of CMV-specific T cells than seropositive recipients of grafts from seronegative donors
(D2R1), and that this is clinically relevant in the setting of in vivo T cell depletion using rabbit-antihuman
thymocyte globulin (ATG). We reviewed charts of 298 ATG-conditioned, seropositive recipients for CMV
reactivation (pp65 antigenemia or CMV DNAemia above institutional threshold for preemptive therapy),
recurrent CMV reactivation, CMV disease, and death. In 77 of these patients, we enumerated CMV-
specific T cells. Median follow-up was 564 days. CMV-specific CD41 and, to a lesser degree, CD81 T cell
counts were higher in D1R1 than D2R1 patients. D1R1 patients had lower cumulative incidence of
CMV reactivation (21% versus 48%, P\.001), recurrent reactivation (4% versus 15%, P5.003), CMV disease
(3% versus 13%, P5.005) and mortality (42% versus 56%, P5.006).We conclude that in the setting of in vivo
T cell depletion using ATG, seropositive donors should be used for seropositive recipients. For scenarios
where only seronegative donors are available, strategies to improve CMV-specific immunity (eg, donor
vaccination) should be explored.
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Allogeneic hematopoietic cell transplantation
(HCT) is followed by a period of immune deficiency.
During this period, endogenous viruses can reactivate
and cause disease, which contributes to HCT recipi-
ents’ morbidity and mortality [1]. Cytomegalovirus
(CMV) reactivation and disease continue to be impor-
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6/j.bbmt.2010.07.020CMV-specific CD41 and CD81 T cells have been
found to play an important role in the control of CMV
replication and progression from reactivation to disease
after transplantation [4-8]. CD4 lymphocytopenia has
been found to be a negative prognostic factor, and
more than half of the patients lacking detectable CMV-
specific T cell responses may subsequently develop
CMV disease [6,9-11].
Among the factors influencing the development of
CMV-specific T cell immunity, CMV donor serostatus
may be important [4,12,13]. Compared to D1R1
patients, D2R1 patients are more likely to develop
CMV reactivation or CMV disease [14-17]. Mortality
of D1R1 and D2R1 patients has been similar;
however, in most patients studied, no T cell depletion
was used [17-21]. Transfer of T cells present in the
allograft from CMV seropositive donors may provide
CMV-specific cellular immunity to the recipient. With
grafts from seropositive donors, both naı¨ve and mem-
ory/effector CMV-specific T cells are transferred.
With grafts from seronegative donors, only naı¨ve
CMV-specific T cells are transferred [22,23]. Whereas
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cell-replete transplantation, it is not known whether this
is of clinical significance in the settingof in vivoTcell de-
pletion.
In our center, since 1999 all allogeneic transplants
have been performed with in vivo T cell depletion using
ATG (Thymoglobulin, Genzyme) for prevention of
graft-versus-host disease (GVHD) [24-26]. ATG delays
T cell recovery and may increase risk of infectious
diseases [27]. Here, we evaluated the role of donor
CMV serostatus on the reconstitution of CMV-specific
T cells and the outcomes after ATG-conditioned trans-
plantation.PATIENTS AND METHODS
Patients
Between January 2005 and September 2008, 77
CMV seropositive recipients of first allogeneic marrow
orblood stemcell transplantation inCalgary for ahema-
tologic malignancy or aplastic anemia (AA) were
accrued into a prospective study of CMV-specific
T cells. These patients signed consent to participate in
this research Ethics Board-approved study. Among the
77patients,D1R1patients appeared tohave lowermor-
tality than D2R1 patients; however, this was not statis-
tically significant. To determine whether statistical
significance would be reached with a larger sample
size, we retrospectively reviewed charts of all CMV se-
ropositive recipients of first allogeneicmarrow or blood
stem cell transplantation in Calgary for a hematologic
malignancy or AA between January 1999 and
September 2008, whose conditioning included ATG
(303 patients including the earlier mentioned 77
patients). Waiver of consent was obtained for the chart
review from the research Ethics Board. Of the 303
patients, 5 developed graft failure (3 D1R1 and 2
D2R1 patients) and were excluded. Thus, 298 patients
were studied for clinical outcomes and 77 patients for
both clinical outcomes and CMV-specific T cell recon-
stitution. Patient characteristics, including the length of
follow-up, are shown inTable 1. Patients were followed
until relapse or death. Median follow-up of the 298 pa-
tients was 564 days (range: 14-3618 days). Minimum
follow-up for patients who have not died or relapsed
was 319 days.Transplantation
Conditioning was given as previously described
[28,29]. Briefly, fludarabine, 50 mg/m2/day intrave-
nously (i.v.), was given on days 26 to 22, and
busulfan, approximately 3.2 mg/kg/day i.v. (with phar-
macokinetic monitoring) was given on days 25 to 22.
Total body irradiation (TBI), two 200 cGy fractions (1
on day21 or and 1 on day 0), was added for some pa-tients. ATG (Thymoglobulin, Genzyme, Cambridge,
MA) was given to all patients; the dose was 0.5 mg/kg
i.v. on day 22, and it was and 2.0 mg/kg on days 21
and0.AApatientswere conditionedwith cyclophospha-
mide, 50mg/kg/day i.v., on days25 to22, plus ATGat
the same dose as for patients with hematologic malig-
nancies. All patients were given cyclosporine A (CsA)
twice daily to maintain blood levels approximately be-
tween 200 and 400 mmol/L, starting on day21 and end-
ing at 3-6 months posttransplant (longer in case of
extensive chronic GVHD [cGVHD]). Methotrexate
(MTX) was given at 15 mg/m2 i.v. on day 1, and 10
mg/m2 on days 3, 6, and 11. Acute GVHD (aGVHD)
was graded according to Glucksberg/Seattle consensus
criteria [30]. Grade II-IV aGVHD was treated with
a corticosteroid with continuation of CsA. cGVHD
was graded as limited (not treated or treated with only
topical immunosuppressive agents) or extensive (treated
with systemic immunosuppression). SignificantGVHD
was defined as grade II-IV aGVHD or extensive
cGVHD.
Supportive care was similar for all patients. All blood
products were from CMV seronegative donors and were
leukocyte depleted. Ciprofloxacin, 500 mg twice a day
orally, was given from day 0 until neutrophil engraftment
until 2003, but not thereafter. No antifungal prophylaxis
wasgiven routinely.Pneumocystis jiroveciiprophylaxis, typ-
ically using trimethoprim-sulfamethoxazole, was given
until 6 months posttransplant or longer (in case of exten-
sive cGVHD). Acyclovir, typically 400 mg twice daily
orally, was used until 6 to 12 months posttransplant or
longer (in case of extensive cGVHD).CMV Monitoring and Therapy
Surveillance for CMV reactivation was performed
weekly from engraftment until typically day 100 after
transplant by pp65 antigenemia assay or CMV DNA
quantitative polymerase chain reaction (PCR) assay.
In the antigenemia assay, CMV immediate early
antigen (IEA) was detected in cells on a slide containing
approximately 200,000 polymorphonuclear cells as
previously described [31]. For the PCR, an in-house
LightCycler based quantitative PCR assay was used
as previously described [32]. Preemptive therapy with
ganciclovir was started whenever pp65 antigenemia ex-
ceeded 10 to 20 positive cells/slide (1999-2007), or
CMV DNAemia exceeded 50,000 copies/mL plasma
(2007-2008). A quality assurance study performed in
early 2007 showed that the antigenemia threshold of
10 to 20 cells/slide is approximately equivalent to the
DNAemia threshold of 50,000 copies/mL. Preemptive
therapy was initiated with ganciclovir at 5 mg/kg i.v.
twice a day for at least 1 week, and continued as main-
tenance at 5 mg/kg i.v. once a day for at least 2 weeks.
Foscarnet was used as an alternative in patients with
neutropenia. Definite CMV disease was treated with
Table 1. Patient Characteristics
77 Patients Studied for CMV-Specific T Cells 298 Patients Studied for Clinical Outcomes
D+R+
n 5 46
D2R+
n 5 31
P
Value
D+R+
n 5 177
D2R+
n 5 121
P
Value
Patient median age (range) 51 (19-62) 50 (22-66) 0.99 49 (20-65) 46 (19-65) .228
Donor median age (range) 38 (19-67) 41 (23-59) 0.48 43 (16-76) 38 (10-66) .016
Sex of donor and recipient
M/M 15(32.6%) 11 (35.5%) 0.616 59 (33.3%) 39 (32.3%) .182
M/F 13 (28.3%) 9 (29.0%) 44 (24.9%) 33 (27.3%)
F/M 12 (26.1%) 2 (6.5%) 40 (22.5%) 25 (20.6%)
F/F 6 (13.0%) 9 (29.0%) 34 (19.3%) 24 (19.8%)
Disease stage*
Good risk 24 (52.2%) 16 (51.6%) 0.961 92 (52.0%) 59 (48.8%) .585
Poor risk 22 (47.8%) 15 (48.4%) 85 (48.0%) 62 (51.2%)
Graft
Bone marrow 0 0 N/A 24 (13.6%) 22 (18.2%) .278
Peripheral stem cells 43 (100.0%) 31(100.0%) 153 (86.4%) 99 (81.8%)
Donor type
HLA matched sibling 26 (56.5%) 12 (38.7%) 0.125 120 (67.8%) 61 (50.4%) .003
Other donor† 20 (43.5%) 19 (61.3%) 57 (32.2%) 60 (49.6%)
HLA match
Fully matched 37 (80.4%) 28 (90.3%) 0.368 154 (87.0%) 99 (81.8%) .094
1 allele-mismatched 8 (17.5%) 2 (6.5%) 18 (10.2%) 18 (14.9%)
>1 allele-mismatched 1 (2.1%) 1 (3.2%) 5 (2.8%) 4 (3.3%)
Conditioning regimen
Flu + Bu 19 (41.3%) 11 (35.5%) 0.678 105 (59.3%) 64 (52.8%) .498
Flu + Bu + TBI 25 (54.3%) 19 (61.3%) 70 (39.5%) 56 (46.3%)
Cyclophosphamide 2 (4.4%) 1 (3.2%) 2 (1.2) 1 (0.8)
Significant GVHD‡ 24 (52.2%) 15 (48.4%) 0.744 82 (46.3%) 48 (39.7%) .255
Acute GHVD Grade 2-4 12 (26.1%) 11 (35.4%) 0.377 32 (19.2%) 28 (23.1%) .412
Chronic GVHD Extensive 21 (45.6%) 13 (41.9%) 0.747 62 (35.2%) 39 (32.2%) .592
Full chimerism§ 37 (97.4%) 21 (100.0%) 0.453 100 (90.1%) 71 (92.2%) .619
End of follow-up in days—Median (range) 635 (45-1519) 414 (63-1249) 0.051 820 (13-3618) 401(17-3249) .017k
Median posttransplant day of d 28 blood draw (range) 28 (25-36) 28 (26-35) 0.419
Median posttransplant day of days 56 blood draw (range) 56 (50-68) 56 (53-68) 0.959
Median posttransplant day of days 84 blood draw (range) 84 (78-95) 84 (79-90) 0.743
Median posttransplant day of days 180 blood draw (range) 183 (165-212) 177 (166-195) 0.599
Median posttransplant day of days 365 blood draw (range) 364 (348-396) 361 (350-428) 0.567
Median posttransplant day of days 730 blood draw (range) 738 (683-747) 728 (714-774) 0.587
GVHD indicates graft-versus-host disease; Flu, fludarabine; Bu, busulfan; TBI, total body irradiation; CMV, cytomegalovirus; GCV, Ganciclovir.
*Good risk disease (pretransplant) was defined as chronic myelogenous leukemia (CML) in first chronic or accelerated phase, acute leukemia in first
remission, myelodysplasia with <5% blasts, aplastic anemia, or myelofibrosis. Poor risk stage disease was defined as any other disease/disease stage.
†A related donor other than an HLA-matched sibling or an unrelated donor.
‡Grade II-IV acute GVHD or extensive chronic GVHD (necessitating systemic therapy).
§Full chimerismwas defined as$90%marrow cells of donor origin at 3 months posttransplant. Chimerism status was missing for 18 patients in the group
of 77 patients and in 110 patients of the total group of 298 patients. The percents shown are percents of cases with known chimerism status.
kWhen considering only patients who did not die, the end of follow-up was 1466 days for the D+R+ patient and 1117 days for the D2R+ patients (P5 .260).
576 Biol Blood Marrow Transplant 17:574-585, 2011A. Ugarte-Torres et al.intravenous immunoglobulin plus ganciclovir or fo-
scarnet.
Definitions of CMV-Related Outcomes
CMV reactivation was defined as antigenemia ex-
ceeding 10 to 20 cells/slide or DNAemia exceeding
50,000/mL plasma. Occasionally, attending physicians
started preemptive therapy with a lower antigenemia/
DNAemia for symptoms/signs suggesting CMV dis-
ease; these cases were also counted as CMV reactiva-
tion. Recurrent CMV reactivation was defined as $2
episodes of CMV reactivation, separated by .14 days
of undetectable CMV. Definite CMV disease was de-
fined according to Ljungman et al. [33]. Possible
CMV disease was defined as symptoms/signs suggest-
ing CMV disease with pp65 antigenemia or CMV
DNAemia under the threshold for preemptive therapytreated per attending physician decision with ganciclo-
vir or foscarnet. Death because of CMV disease was de-
fined as autopsy findings consistent with CMV disease
or, in the absence of autopsy, death that followed defi-
nite CMV disease judged to cause the death (eg, severe
pneumonia).
CMV-Specific T Cell Enumeration
HumanCMVwhole virus lysate, strain AD169, pro-
duced in a human foreskin fibroblast cell line, was pur-
chased from Advanced Biotechnologies, Columbia,
MD.Amixture of overlapping 15-mer peptides spanning
the CMVpp65 protein was purchased from JPT (Berlin,
Germany).Peripheralbloodmononuclear cells (PBMCs)
were isolated fromheparinized blood by density gradient
separation using Lympholyte-H (Cedarlane, Burlington,
ON). One million fresh (not cryopreserved) PBMCs
Biol Blood Marrow Transplant 17:574-585, 2011 577CMV-Specific Immunity in D+R+ versus D2R+ Patientswere cultured with 5 mg/mLCMV lysate, 2 mg/mL pp65
overlapping peptides, 5 mg/mL staphylococcal entero-
toxin B (SEB, Sigma, Toronto, ON, positive control)
or no stimulus (negative control) in the presence of 2.5
mg/mL CD28 antibody (BD Bioscience, Toronto, ON)
in a final volume of 0.5 mL complete medium. Com-
plete medium was composed of RPMI1640, 2 mM
L-glutamine, 100 U/mL Penicillin, 0.1 mg/mL Strepto-
mycin (Sigma, Toronto, ON) and 10% fetal bovine
serum. In preliminary experiments we showed that the
background was similar when using complete medium
alone, complete medium with uninfected foreskin fibro-
blast cell line lysate, or complete medium with HIV gag
overlapping peptides (all patients and donors were free
of HIV infection). Thus, for economy, media alone was
used as negative control. PBMCs were cultured for 18
hours. After the first 2 hours of culture, 35 mL of 1:43 di-
luted brefeldin A (Golgistop, BD Bioscience) was added.
Cells were washed with PBS containing 1% fetal bovine
serum and 0.1% sodium azide, and fixed and permeabi-
lized using the Cytofix/Cytoperm kit from BD Biosci-
ence according to manufacturer’s instructions. Cells
were stained with the following fluorochrome-labeled
antibodies: allophycocyanin-CD3 (Coulter Immuno-
tech, Toronto, ON), phycoerythrin-Cy5-CD4 (CoulterFigure 1. Enumeration of CMV-specific T cells. Example dot plots showing se
cells/ IFNg1 cells (see arrows above the top row of dot plots). The subsets w
responding to (A) no stimulus (negative control), (B) CMV lysate (‘‘CMV lysa
cells), and (D) staphylococcal enterotoxin B (positive control). Dashed gray l
gate moved 1 fluorescence log to the right to enumerate the IFNghigh cells.Immunotech), fluorescein isothiocyanate-CD8 (BD
Pharmigen, Toronto, ON), and phycoerythrin-IFNg
(Miltenyi Biotec, Auburn, CA). Staining was performed
in the dark for 30 minutes at 4C. Cells were washed
withPBS containing 1% fetal bovine serumand0.1%so-
dium azide. Flow cytometry was performed using FacsA-
ria (BD Biosciences, San Jose, CA). Thirty thousand
CD31CD41 cells were acquiredwhenever possible. Per-
centages of IFNg1 cells among CD31CD41 or
CD31CD81 cells were determined using WinList soft-
ware (Verity Software House Inc., Topsham, ME) as
shown inFigure1.Todetermine thepercentagesof IFN-
ghigh cells amongCD31CD41 orCD31CD81 cells, the
left border of the gate for the IFNg1 cells on each IFNg
versus CD4 (CD8) plot was moved arbitrarily by 1 fluo-
rescence log to the right (see dashed gray lines in
Figure 1). Background signals from unstimulated cells
(negative control) were subtracted. Absolute counts (per
microliter of blood) were determined using bloodmono-
nuclear cell counts (absolute monocyte count1 absolute
lymphocyte count) determined by a routine hematology
laboratory.
To determine the detection limit of the assay, we
diluted CMV lysate- or pp65-stimulated cells into
autologous nonstimulated cells. In 9 individuals, wequential gating of mononuclear cells/ CD31 cells/ CD41 (CD81)
e enumerated were CD31CD41 IFNg1 and CD31CD81 IFNg1 cells
te-specific’’ cells), (C) CMV-pp65 overlapping peptides (‘‘pp65-specific’’
ines on IFNg versus CD4 (CD8) plots represent the left border of the
578 Biol Blood Marrow Transplant 17:574-585, 2011A. Ugarte-Torres et al.determined the percentages of IFNg1 CD4 (CD8)
cells for all dilutions. The results were plotted as ob-
served percentages versus expected percentages. The
detection limit was determined by visually inspecting
the plots (see Supplementary Figure 1). The detection
limit was set to 0.01% for all subsets. Results below
0.01% were arbitrarily assigned a value of zero.
IFNg expression has been shown to be higher on
polyfunctional T cells (having other effector functions
like producing TNFa and IL2 in addition to IFNg)
than unifunctional T cells (secreting only IFNg)
[34,35]. To evaluate whether this is also true in our
setting, in 17 early posttransplant patients (day 56) and
7 late posttransplant patients (day 365), we measured
the median fluorescence intensity (MFI) of the
fluorochrome conjugated to the IFNg antibody on
unifunctional, bifunctional, and trifunctional CMV-
specific T cells. Unifunctional cells were defined as
those expressing only IFNg, bifunctional cells as those
expressing IFNg together with IL2 and not TNFa or
with TNFa and not IL2, and trifunctional cells as those
expressing all 3 cytokines. Peripheral blood mononu-
clear cells (PBMCs) were stimulated, incubated, and
stained as described before, except stained for not only
IFNg but also for IL2 and TNFa. The following
antibodies were used, PE-Cy7-CD3 (eBiosciece, San
Diego,CA),Alexa700-CD3(BDPharmigen), eFluor450-
CD4(eBioscience), eFluor605-CD8, PE-IFNg (Miltenyi
Biotec, Auburn, CA), PE-Cy-7- IFNg (eBioscience),
FITC-TNFa (eBioscience), and APC-IL2 (eBioscience),
In samples with cytokine expression above background
levels, the MFI of IFNg was determined on CD4 and
CD8 T cells producing IFNg only, IFNg and TNFa or
IFNg and IL2, or all 3 cytokines (IFNg,TNFa, and IL2).
CMV Serostatus Determination
CMV-specific IgG in serumwasdeterminedbyami-
croplate enzyme immunoassay (Siemens Enzygnost,
Marburg, Germany) in accordance with the manufac-
turer’s instructions. All pipetting was performed by an
automated robotic dispenser (BEP 11). A positive result
was defined as an absorbance of.0.2, a negative result as
\0.1, and equivocal result as in the range of 0.1 to 0.2. If
equivocal, blood was redrawn and the assay was rerun. If
equivocal also on the second determination, the patient
or donor serostatus was called indeterminate (for trans-
plants performed between January 2005 and September
2008, this applied to 2 recipients [andnodonor]; the2 re-
cipients were not included in this study). Appropriate
controls were included with each run to ensure that the
assay met defined parameters.
Statistical Analysis
In univariate analyses, patient groups were com-
pared using the chi-square test for categorical variables,
and the Mann-Whitney rank-sum test for continuousvariables. In multivariate analyses to compare the
D1R1 and D2R1 patients for cumulative incidence
of firstCMVreactivation, recurrentCMVreactivation,
and CMV disease, a generalized linear model (GLM)
with a Poisson distribution and robust error variance,
and a log link was used [36], including the following
covariates: donor age (included because of imbalance
of donor age between the D1R1 and D2R1 patients),
donor type (matched sibling versus other), and signifi-
cant GVHD (yes vs no). For relapse, nonrelapse death,
and death, the following covariates were added: patient
age, and disease stage (for the definitions of the covari-
ates, see footnotes on Table 1). To compare the D1R1
and D2R1 patients for time to first CMV reactivation,
time to recurrent reactivation (first of themultiple reac-
tivations), time toCMVdisease, and time to death,Cox
proportional hazard analysis was performed using the
same covariates. When considering relapse and nonre-
lapse mortality, each of which are competing risks, the
Fine andGraymethodwas used [37]. A 2-sided P-value
\.05 was considered statistically significant. Analysis
was performed using STATA software, version 11.
Data were analyzed by TW and AUT. All the authors
had access to primary database.RESULTS
Reconstitution of CMV-Specific T Cells after
Transplantation Depends on Donor Serostatus
As shown in Table 1, among the 77 patients stud-
ied for CMV-specific T cell reconstitution, the D1R1
and D-R1 groups were balanced for all characteristics.
IFNg1 CD4 T cells
As shown in Figure 2, percents of CMV lysate-
specific cells amongCD4Tcells aswell as their absolute
counts were significantly higher in D1R1 than D2R1
patients throughout the first 2 years after transplant.
Percents as well as absolute counts of pp65-specific
CD4 T cells were also higher in D1R1 patients; this
reached statistical significance on day 56, 84, and 180.
Most D1R1 patients reached the low normal limit
(10th percentile of CMV seropositive donors) already
by day 28, whereas most D2R1 patients reached the
low normal limit later—between day 180 and 365
(Figure 2B). On day 56, the CMV-specific CD4 T cells
appeared to contribute substantially to the total CD4T
cell pool, as the total CD4T cell count was significantly
higher in D1R1 than D2R1 patients (Supplementary
Figure 2).
IFNg1 CD8 T cells
In contrast to CD4 T cells, there was only a trend
toward higher percents and absolute counts of
CMV lysate-specific CD8 T cells in D1R1 compared
Figure 2. Impact of the donor CMV serostatus on CMV-specific T cells. Percents (A) and absolute counts (B) of IFNg1 cells are displayed on the y-axes.
Black lines represent D1R1 and gray lines D-R1 recipients. The dotted lines represent the 10th and 90th percentiles of CMV seropositive donors
(healthy controls). The number of patients studied at each time point is given in the tables at the bottom. Asterisks denote significance (P\.05).
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the percents and counts were similar late (at 1 and 2
years) posttransplant. Percents and absolute counts
of pp65-specific CD8 T cells were significantly higher
in D1R1 patients also early but not late after trans-
plant (Figure 2). Most D1R1 patients showed an
‘‘overshoot’’ (absolute counts of pp65-specific CD8
T cells above the high normal limit, ie, 90th percentile
of CMV seropositive donors, presumed reaction to
detectable or undetectable CMV reactivation) on
days 56, 84, and 180, whereas most D2R1 patients
did not show the ‘‘overshoot’’ (Figure 2B).
IFNghigh T cells
IFNg producing T cells include both polyfunc-
tional and unifunctional cells. The polyfunctional T
cells express high levels of IFNg, whereas the unifunc-
tional T cells express low levels of IFNg (this has been
reported [34,35] and is also suggested by our data
presented in Supplementary Figure 3). The polyfunc-
tional T cells are expected to be more relevant for
patient protection from CMV disease [17]. Thus, we
enumerated IFNghighTcells as surrogates for polyfunc-
tional T cells. As shown in Supplementary Figure 4, the
comparison of the reconstitution of IFNghigh T cells
between D1R1 and D2R1 patients mirrored that of
IFNg1T cells, that is, the percents and absolute countsof IFNghighCD4Tcells appeared tobehigher inD1R1
patients both early and late posttransplant, whereas the
percents and absolute counts of IFNghigh CD8 T cells
appeared to be higher in D1R1 patients early but not
late posttransplant.
Incidences of CMV Reactivation and CMV
Disease Depend on Donor Serostatus
As shown in Table 1, the 298 patients (177 D1R1
and 121D2R1 patients) were balanced formost charac-
teristics, except for donor age (higher in D1R1 patient-
s),donor type (higher proportion of HLA-matched
siblings in D1R1 patients), and the length of follow-
up (longer in D1R1 patients). The higher proportion
of HLA-matched siblings in D1R1 patients has been
described [17] and may reflect the similarity of CMV
serostatus among siblings. The imbalances of donor
age and donor type were adjusted for in the multivariate
analyses. No adjustment was done for the imbalance in
the length of follow-up for the following 2 reasons: first,
it was at least in part because of the lower mortality of
D1R1 than D2R1 patients, as there was no significant
difference in the length of follow-up when considering
only patients who did not die (median 1466 versus
1117 days, P5 .260). Second, fewer events (CMV reac-
tivation, recurrent reactivation, or CMV disease) were
noted in the group with longer follow-up (D1R1
Table 2. Outcomes of 298 Patients According to Donor CMV Serostatus.
Unadjusted
(Univariate Analysis)
Adjusted
(Multivariate Analysis)
D+R+
n 5 177
D-R+
n 5 121 RR CI 95% P Value RR CI 95% P Value
CMV reactivation above threshold for GCV
preemptive therapy; n (%)
37 (20.9%) 58 (47.9%) 0.43 0.31-0.61 <.001 0.45 0.32-0.64 <.001
Recurrent reactivation above threshold for GCV
preemptive therapy; n (%)
7 (3.9%) 18 (14.8%) 0.26 0.11-0.61 .002 0.28 0.12-0.68 .005
Definite CMV disease; n (%) 5 (2.8%) 15 (12.4%) 0.22 0.08-0.61 .003 0.25 0.09-0.67 .006
Gastroenteritis 3 (1.7%) 10 (8.3%) 0.20 0.05-0.72 .014 0.19 0.06-0.69 .011
Pneumonia 0 (0%) 5 (4.1%) — — .006* — — —
Chorioretinitis 2 (1.1%) 0 (0%) — — .241* — — —
Definite + presumed CMV disease; n (%) 7 (3.4%) 16 (13.2%) 0.30 0.12-0.72 .008 0.28 0.11-0.71 .007
Fatal CMV disease; n (%) 1 (0.6%) 3 (2.5%) 0.22 0.02-2.16 .198 0.32 0.04-2.47 .276
Relapse; n (%) 60 (33.9%) 46 (38.2%) 0.89 0.65-1.21 .465 0.81 0.60-1.08 .150
Death (because of any cause); n (%) 74 (41.8%) 68 (56.2%) 0.74 0.59-0.94 .013 0.73 0.58-0.91 .006
Nonrelapse death; n (%) 29 (16.4%) 30 (24.8%) 0.66 0.42-1.04 .074 0.64 0.41-1.02 .059
GCV indicates ganciclovir; RR, relative risk; CI, confidence interval.
*Tested by chi-square test, as binomial regression is inappropriate for scenarios of no events in a group. For the same reason, multivariate analysis was
not done.
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attributed to shorter follow-up.
D2R1 patients had approximately 2-fold higher
risk of CMV reactivation, 4-fold higher risk of recur-
rent CMV reactivation and 4-fold higher risk of defi-
nite CMV disease (Table 2 and Figure 3).
Twenty patients developed definite CMV disease,
5 (2.8%) inD1R1 group, comparedwith 15 (12.4%) in
D2R1 group (P 5 .003). Similar difference between
the D1R1 and D2R1 groups was observed when both
definite and possible CMV disease was considered—
there were 7 (3.4%) cases of definite or presumed
CMV disease in the D1R1 group, compared with 16
(13.2%) in the D2R1 group (P 5 .008). The most
common definite CMV disease was gastrointestinal—
there were 3 cases (1.7%) in D1R1 group and 10 cases
(8.3%) in D2R1 group (P 5 .014). CMV pneumonia
occurred in 0 (0%) D1R1 patients and 6 (4.1%)
D2R1 patients (P 5 .006). Four patients developed
fatal CMV disease, 1 of them was D1R1 (had
gastroenteritis) and 3 of themwereD2R1 (2 had pneu-
monia and 1 had gastroenteritis).
Late definite CMV disease (diagnosed after 100
days posttransplant) was mostly observed among the
D2R1 recipients. There were 5 cases amongD2R1 pa-
tients (gastroenteritis, 3, pneumonia, 2) and 1 case
among D1R1 patients (chorioretinitis).Mortality depends on donor CMV serostatus
One hundred forty-two of the 298 patients (47.6%)
died. Seventy percent of all deaths occurred during the
first year after transplant, and 49% within the first 6
months. As shown in Table 2 and Figure 3, the D1R1
group had lower mortality compared to D2R1 group
(41.8% versus 56.2%, relative risk [RR] 5 0.74, P 5.006 [GLM]). Time from transplant to death was also
longer for the D1R1 than D2R1 patients (median
time to death 6.3 versus 5.4 months, hazard ratio
[HR]5 0.62,P5 .007 [Cox]).Therewas a trend toward
lower nonrelapse mortality (NRM) in the D1R1
than D2R1 group (16.4% versus 24.8%; RR 5 0.66,
P5 .059 [GLM]).Consistentwith that, therewasa trend
toward longer time to nonrelapse death in D1R1 than
D2R1 patients (4.1 versus 3.5 months, subhazard ratio
[SHR] 5 0.60, P 5 .060 [Cox]). Relapse rates in
D1R1 and D2R1 patients appeared similar (33.9%
versus 38.2%, RR 5 0.81, P 5 .150 [GLM]). Time to
relapse was also similar (7.3 versus 7.6 months, SHR5
0.89, P5 .460 [Cox]).DISCUSSION
The 2 essential findings of this study are (1) that
CMV-specific CD4 T cell counts are higher in
D1R1 compared to D2R1 patients, and (2) that this
appears to lead to survival advantage (as the D2R1 pa-
tients had higher mortality than the D1R1 patients).
Our analysis focused on CMV seropositive recipi-
ents, who are known to be particularly susceptible to
CMV-related complications [3]. The results suggest
that having a CMV-positive donor is associated with
higher counts of CMV-specific CD4T cells. The larg-
est study on this subject published so far focused on
CD8 T cells, and showed that CMV-specific CD8 T
cell counts were higher in the D1R1 patients [17]. In
contrast, in our study the difference in CMV-specific
CD8 T cell counts was only marginal and reached sta-
tistical significance at only some early time points,
whereas the difference in specific CD4 T cell counts
was highly significant at most time points, both early
Figure 3. Cumulative incidence of outcomes according to CMV donor serostatus. Kaplan Meier plots show the cumulative incidence of CMV reac-
tivation, recurrent CMV reactivation, CMV disease, relapse, death from any cause, and nonrelapse death. Black lines represent D1R1 and gray lines
D2R1 recipients.
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with studies measuring lymphoproliferative or cyto-
toxicity response in PBMCs, indicating that a major
risk factor for delayed T cell response is receiving
a graft from a CMV negative donor [4,13,14,38-40].
Higher CD4 T cell responses were elicited by
CMV lysate than pp65 overlapping peptides, whereas
higher CD8 T cell responses were elicited by pp65
overlapping peptides than CMV lysate. This could
be because CD8 T cell response is predominantly spe-
cific for peptides derived from structural viral proteins
[41], or because the lysate contains predominantly
proteins or large peptides that can be processed and
presented to primarily CD4 T cells. Also, a limited
number of clones of CMV-specific CD4 T cells
are present in chronically infected individuals [42]
so theoretically few CD4 clones specific for pp65peptides could be present in the grafts and posttrans-
plant patients.
As the lack of CMV-specific immunity is a risk
factor for developing CMV complications [10,13,
43,44] we evaluated whether the negative donor
serostatus, associated with barely detectable CMV-
specific T cells posttransplant, translates into higher
rates of CMV complications. As expected [14,17] we
found higher rates of CMV reactivation requiring
preemptive therapy, recurrent reactivation, and
CMV disease in patients who received grafts from
seronegative donors.
The survival difference between the D1R1 and
D2R1 patients in our study is a novel finding. It needs
to be interpreted in the light of published reports
(Table 3). Reports on patients undergoing T cell-
replete transplantation did not show any survival
Table 3. Previous Studies Analyzing Outcomes of D+R+ and D2R+ Patients
Transplant Center or Group Number of Patients
T Cell Depletion
(in vivo or ex vivo) Relapse Difference Nonrelapse Mortality Difference Survival Difference
City of Hope (Zhou et al, Blood, 2009) [17] 178 Yes 0%
No 100%
Not reported Not reported No significant difference
Seattle (Nichols et al, J Infect Dis 2002) [18] 1750 Yes 0%
No 100%
Not reported Not reported Significance of difference not
reported, appearance
of D+R+ < D2R+
European Blood and Marrow Transplant
(Ljungman et al, Blood 2003) [19]
7018 Yes 20%
(mostly ex vivo)
No 80%
No significant difference No significant difference,
except for subgroups
(D+R+ < D2R+ in unrelated
donor HCT recipients and in
patients with CML)
No significant difference, except
for subgroups
(D+R+ > D2R+ in unrelated
donor HCT recipients and in
patients with CML)
National Marrow Donor Program
(Kollman et al, Blood 2001) [20]
6978 (unrelated donor HCT
recipients)
Yes 25%
(mostly ex vivo)
No 75%
No significant difference Not reported No significant difference
European Blood and Marrow Transplant
(Cwynarski et al, Blood, 2003) [21]
314 (pediatric patients
with CML)
Yes 34%
(mostly ex vivo)
No 66%
Not reported Not reported No significant difference
London (Craddock et al, BJH 2001) [45] 36 (patients with CML) Yes 100% (mostly in vivo
alemtuzumab)
No 0%
Not reported Not reported No significant difference
Vienna (Matthes-Martin et al, BMT 2003) [46] 129 (pediatric patients) Yes 74%
(mostly in vivo ATG)
No 26%
Not reported Significance of difference not
reported, appearance
of D+R+<D-R+
Not reported
Stockholm (Ringden et al, BBMT 2004) [38] 136 (unrelated donor HCT
recipients)
Yes 99%
(mostly in vivo ATG)
No 1%
Not reported Significance of difference not
reported, appearance
of D+R+<D-R+
Significance of difference not
reported, appearance
of D+R+ > D2R+
Hamburg (Kroger et al, Brit J Haematol 2001) [47] 125 Yes 100%
(all in vivo ATG)
No 0%
Not reported Not reported Significance of difference not
reported, appearance
of D+R+ > D2R+
CML indicates chronic myelogenous leukemia; ATG, antithymocyte globulin.
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included patients undergoing transplantation using
T cell depletion performed ex vivo or achieved in vivo
with alemtuzumab were also generally negative for
a survival difference between D1R1 and D2R1
patients [19-21,45]. Only 3 reports exist in which most
or all patients underwent transplantation using in vivo
T cell depletion with ATG [38,46,47]. None of the 3
reports, focused on the comparison of D1R1 versus
D2R1 patients. However, based on the data presented
in the reports, there appears to be at least a trend
toward lower nonrelapse mortality and/or higher
survival in D1R1 than D2R1 patients. Given that
ATG was also given to all patients in our study, we
speculate that the survival advantage of D1R1 patients
is related to the ATG administration with
conditioning. This is probably not solely because of
ATGkillingCMV-specificT cells infusedwith the graft,
as ex vivo depletion of T cells from the graft has not re-
sulted in an increased survival of D1R1 over D2R1 pa-
tients [19]. Perhaps, the combined effect of in vivo
administered ATG on both the donor CMV-specific
T cells infused with the graft and the recipient CMV-
specific T cells surviving conditioning (that are capable
of suppressing CMV posttransplant [23]) is important.
Perhaps, the in vivo administered ATG kills or sup-
presses reconstituting NK cells or other cells participat-
ing in innate immunity that may be important in
defense against CMV. We cannot explain why the sur-
vival advantage of D1R1 patients was not observed
after in vivo T cell depletion with alemtuzumab [45].
One possible explanation is that only 36 patients were in-
cluded in that study. Also, mechanisms of action of ATG
and alemtuzumab are not identical. For example, ATG
butnot alemtuzumabhasbeendescribed to inducediffer-
entiation ofT cells to regulatoryTcells [48].What could
be the reason for no survival advantage of theD1R1 over
the D2R1 patients in the setting of T cell-replete trans-
plantation versus survival advantage in the setting of in
vivo T cell depletion with ATG? Perhaps the T cell-
replete grafts from seronegative donors contain enough
naı¨ve CMV-specific T cells that can differentiate early
posttransplant into memory/effector CMV-specific
T cells and protect the recipient against CMV complica-
tions and/or that the few recipient CMV-specific T cells
surviving the conditioning protect the patient against
CMV complications. These processes may be inhibited
by ATG [49].
However, improved protection of D1R1 over
D2R1 patients from CMV disease is likely not the
main reason for improved survival, as CMV disease
caused death rarely (Table 2). The main reason re-
mains obscure but the main influence seems to be on
nonrelapse mortality (Table 2). It cannot be attributed
to GVHD induction by the frequent CMV reactiva-
tions [50] in the D2R1 patients, as the incidences ofsignificant GVHD, aGVHD grade II-IV, as well as
extensive cGVHD were similar in both patient groups
(Table 1). Hypothetically, the higher number of
courses of ganciclovir/foscarnet in the D2R1 patients
could contribute to death because of the toxicity of the
drugs.
A limitation of this study is that by chance the total
cohort evaluated for clinical outcomes (n 5 298) and
the subcohort evaluated for CMV-specific T cells
(n 5 77) may have differed. For example, donor age
was significantly higher in the D1R1 than the D2R1
patients of the total cohort, whereas the median donor
age was nonsignificantly lower in the D1R1 that the
D2R1 patients in the subcohort (Table 1). Partly be-
cause of this, the cause and effect relation between
the higher CMV-specific T cell counts and the lower
incidence of CMV disease or overall mortality among
D1R1 patients should not be considered proven. Nev-
ertheless, it is reassuring that themain outcomes of this
study, CMV disease incidence and overall mortality,
were significantly or near-significantly lower in
D1R1 than D2R1 patients in both cohorts (Table 2
and Supplementary Table 1).
In summary, for CMV seropositive patients in the
setting of in vivoT cell depletion with ATG, a seropos-
itive donor should be preferred. If a seropositive donor
is not available, strategies to improve CMV-specific
immunity (eg, donor pretransplant vaccination, or in-
fusion of CMV-specific memory/effector T cells gen-
erated ex vivo from donor CMV-specific naı¨ve T cells)
should be explored.ACKNOWLEDGMENTS
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